Sep 13, 2026 · 32 min
Biotech’s rally tests the promise of cancer breakthroughs
A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?
Investors must decide whether excitement around cancer vaccines, AI and new drug platforms reflects durable growth or inflated valuations.
- 1Easing regulatory fears and enthusiasm for AI helped lift both major pharmaceutical companies and smaller biotechs.
- 2Moderna’s cancer-vaccine rally may already reflect substantial future revenue, while Revolution Medicines presents a clearer growth story.
- 3China’s faster drug development and uncertain clinical data are raising a new competitive and investment challenge for U.S. pharma.
Don't miss
The China discussion compares fast-following drug development with the market shock caused by DeepSeek and raises questions about a treatment that could challenge Merck’s Keytruda.
The brief
Biotech has outperformed as regulatory fears eased and investors returned to healthcare, but the rally rests on more than one story: AI, new drug platforms and defensive positioning all matter.
The discussion tests whether Moderna’s personalized cancer-vaccine excitement justifies its valuation, contrasting it with Revolution Medicines’ more legible growth path.
Pharma is moving away from mega-mergers toward smaller, targeted acquisitions, using a venture-capital-like approach to replenish pipelines while AI improves development without replacing human trials.
The GLP-1 market shows how quickly leadership can change: Novo Nordisk’s stock fell as Eli Lilly’s more powerful competing drugs gained share.
China’s advancing biotech industry could challenge U.S. drugmakers, while unresolved survival data and an accelerated Huntington’s therapy approval expose the stakes of betting on uncertain science.
Featuring
Zepbound
Wegovy
The Wall Street JournalListen to the full episode and explore every guest, topic, and moment on PodLume.